Skip to main content

Table 4 Univariable and multivariable cox analysis of OS after propensity matched analysis

From: Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis

Variable Univariable Univariable
HR 95% CI P HR 95% CI P
Age (≥60/< 60, year) 0.922 0.463–1.837 0.818
Sex (Men/Women) 1.458 0.689–3.087 0.324
HBsAg (yes/no) 1.711 0.887–3.300 0.109
HCV antibody (yes/no) 6.405 1.491–27.524 0.013 9.142 2.028–41.225 0.004
AFP (≥20/< 20, ng/mL) 1.288 0.761–2.181 0.346
CEA (≥5/<5, ng/mL) 1.643 0.924–2.923 0.091
CA19–9 (≥37/<37, U/mL) 1.591 0.932–2.715 0.089
Liver cirrhosis, yes (%) 1.952 1.091–3.493 1.379 6.264 0.734–2.590 0.318
TB (≥17/< 17, μmol/L) 0.739 0.383–1.427 0.368
ALB (≥40/<40, g/mL) 0.814 0.476–1.391 0.451
ALT (≥35/<35, U/L) 1.459 0.869–2.452 0.153
γ-GT (≥40/<40, U/L) 1.811 0.933–3.515 0.079
PLT (≥10/< 10 103/μL) 1.353 0.683–2.682 0.386
Prothrombin time, median (range), s 1.014 0.547–1.880 0.964
Tumour size, cm 1.466 0.814–2.639 0.203
Tumour nodularities 1.017 0.785–1.318 0.898
Occlusion, min (< 20/≥20) 1.560 0.735–3.310 0.247
Macrovascular invasion (yes/no) 3.343 1.770–6.315 < 0.001 3.035 1.543–5.972 0.001
Microvascular invasion (yes/no) 1.359 0.725–2.546 0.338
Lymphoid metastasis (yes/no) 1.487 0.667–3.315 0.332
Extrahepatic metastasis (yes/no) 6.805 2.549–18.166 < 0.001 6.264 2.277–17.235 < 0.001
Preventive TACE (yes/no) 0.911 0.545–1.520 0.720
  1. HBsAg hepatitis B surface antigen, HCV hepatitis C virus, AFP α-fetoprotein, CEA carcino-embryonic antigen, CA19–9 carbohydrate 19–9, TB total bilirubin, ALB albumin, ALT alanine aminotransferase, γ-GT γ-glutamyl transpeptidase, PLT platelet, ALP alkaline phosphatase
\